Navigation Links
World's Largest Study on Insulin Therapy Completes Recruitment With 60,000 Patients
Date:7/19/2010

ZURICH, July 19, 2010 /PRNewswire/ -- Today, Novo Nordisk announced the landmark recruitment of the 60,000th patient in the A1chieve(R) study - an observational study designed to investigate the effects of modern insulins in the management of type 2 diabetes.[1]

Spanning 28 countries across 4 continents and involving more than 3300 physicians, A1chieve(R) is set to be the world's largest observational study in insulin therapy.

Approximately 70 percent of the world's 285 million people with diabetes are living in these 28 emerging countries where there is a rising need and interest to look at differences in physician decisions in the management of diabetes.[2]

"Multinational observational studies like A1chieve(R) provide valuable insights in the way current therapies are applied when it comes to varying cultural, economic and epidemiological circumstances," said Philip Home, Professor of Diabetes Medicine at Newcastle University England and Chair of the A1chieve(R) Global Advisory Board.

In order to mimic the natural secretion of insulin in the body, commercially available insulin preparations are used in different ways (regimens) based on an individual's need and prevailing local practices. However it is important to evaluate these different regimens in a real life setting.

"Once completed A1chieve(R) will provide locally relevant information on the effective use of modern insulins across different regimens. This information could be further useful to inform and improve the local guidelines on the management of type 2 diabetes" added Professor Home.

Jesper H0iland, Senior Vice President, Novo Nordisk Region International Operations A/S said "The A1chieve(R) study is another major initiative demonstrating our commitment as leaders in the field of diabetes care. Our vast experience and unmatched presence in the emerging countries has enabled us to carry out such a unique and large scale research activity of clinical importance."

The results of this multinational study will be available in 2011.

Novo Nordisk is a healthcare company and a world leader in diabetes care. In addition, Novo Nordisk has a leading position within areas such as haemostasis management, growth hormone therapy and hormone replacement therapy. Novo Nordisk manufactures and markets pharmaceutical products and services that make a significant difference to patients, the medical profession and society. With headquarters in Denmark, Novo Nordisk employs more than 28,500 employees in 81 countries, and markets its products in 179 countries. Novo Nordisk's B shares are listed on the stock exchanges in Copenhagen and London. Its ADRs are listed on the New York Stock Exchange under the symbol 'NVO'. For more information, visit http://www.novonordisk.com.

    Further information:

    References

    1. Siddharth N. Shah, Leon Litwak, Jihad Haddad, Praful N. Chakkarwar and
    Issam Hajjaji. The A1chieve(R) study: a 60,000-person, global,
    prospective, observational study of basal, meal, and biphasic insulin
    analogs in daily clinical practice. Diabetes Research and Clinical
    Practice 88S (2010).

    2. IDF Diabetes Atlas 4th Edition, International Diabetes Federation,
    2009. http://www.diabetesatlas.org.


'/>"/>
SOURCE Novo Nordisk
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. New Study Presented at WorldSleep 2007 Demonstrates Ramelteon Has Sustained Efficacy Over Six Months in Adults With Chronic Insomnia
2. Frankfurt To Host Worlds Largest Pharmaceutical Services Events In 2011
3. Genomic Health Announces Results From the Largest Genomic Analysis of Localized Clear Cell Renal Carcinoma at American Society of Clinical Oncology (ASCO) Annual Meeting
4. Largest Civil Settlement in Pharmaceutical Case Announced by U.S. Department of Justice
5. CyberKnife Radiosurgery Now Reimbursed Throughout France and Largest Italian Region
6. First European Patients Enrolled in Largest Ever Randomised Controlled Trial of ITB Therapy(R) in Post-Stroke Patients With Severe Spasticity
7. New York States Largest Integrated Health System Chooses Craneware Revenue Integrity Solutions
8. Russias Largest Breast Cancer Oncology Center Uses New CAD Software for Advanced Breast Cancer Detection
9. Daiichi Sankyo Initiates Largest Single, Double-Blind, Randomized, Phase III Trial for Treatment and Prevention of Recurrent Venous Thromboembolism
10. U.S. Files Suit Against Johnson & Johnson For Paying Kickbacks to Nations Largest Nursing Home Pharmacy
11. At Nearly $120 Million, The Hepatitis C Drug Market in Brazil is Among the Largest Emerging Pharmaceutical Markets for the Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2016)... 2016 The innovator of ... , s first dual therapy stent, introduces catheters ... OrbusNeich, a global company specializing in the provision ... include products to treat peripheral artery disease. The JADE™ ... devices for lower limb and arteriovenous (AV) fistula intervention. ...
(Date:5/24/2016)... , May 24, 2016 Dutch surgeons ... best practices around the world and treat patients on a global ... Africa , Asia and the US ... with instant messaging and networking in a totally secure environment. ... in a war zone working together with a surgeon at Harvard ...
(Date:5/23/2016)... FLINT, Mich. , May 23, 2016 Diplomat ... the third annual Fellowship and Internship programs. The hands-on ... 12. The full-time, paid Fellowship ... Flint, Michigan . Fellows and interns are ... downtown Flint at the Riverfront ...
Breaking Medicine Technology:
(Date:5/24/2016)... ... May 24, 2016 , ... Educational opportunities, ... housing, with more advantaged communities providing richer opportunities. Recognizing the key role of ... school improvement policies; (b) school choice policies; (c) school desegregation policies; (d) wealth-focused ...
(Date:5/24/2016)... ... ... New Brunswick, New Jersey: This year marks Children’s Specialized Hospital ’s 125th anniversary ... anniversary, the hospital has themed the milestone “Hats Off” and kicked off the yearlong ... Saturday, May 21, at Johnson Park in Piscataway, New Jersey. , “Hats ...
(Date:5/24/2016)... ... (PRWEB) May 24, 2016 -- Grow Healthy ... Advisory Board. Joining the Grow Healthy Advisory Board team are ... embody the mission of our organization and bring talent, expertise and ... as we continue to expand our footprint as the leader in ...
(Date:5/24/2016)... ... May 24, 2016 , ... Boyd Industries, a leading supplier of ... groundbreaking new product for pediatric dentistry , at AAPD 2016, the annual conference ... May 26-29. The Concealed Delivery Unit keeps dental hand pieces and other anxiety-provoking pieces ...
(Date:5/24/2016)... ... May 24, 2016 , ... Eggsurance, the first independent, non-clinic ... its community and education hub for women considering fertility preservation, as well as ... safe and welcoming place for women to find cycle buddies, get clinic recommendations ...
Breaking Medicine News(10 mins):